which are hormone-dependent, regressing following oophorectomy but regrowing after oestrogen administration (Huggins, 1963) . In these tumours, regression may also be produced by administration of 5a-reduced steroids (Huggins, Briziarelli and Sutton, 1959; Huggins and Mainzer, 1957) . It is therefore of interest that DMBAinduced rat mammary tumours have the potential to synthesize 5a-reduced steroids (King, Gordon and Helfenstein, 1964; Miller, Forrest and Hamilton, 1974) . The aim of the present study was to determine the effects of oestrogen on tumour 50c-reduction of testosterone.
Tumours were induced in randomly bred female Sprague Dawley rats by intravenous administration of 5 mg DMBA at 50 days of age. When the tumours were approximately 2 x 2 cm in size the rats were oophorectomized. Fourteen days after oophorectomy the animals were given daily subcutaneous injections of oestradiol-17,8 oestradiol-17,8 (1.5 ,ug/ml) to determine the effects of oestrogen. Both systems were then incubated by shaking at 37°C in an atmosphere of oxygen for 1 h. The reaction was stopped by adding methanol (60 ml) and the incubations were stored at -I0C until the steroids were isolated and characterized.
Before extraction, 500 ,tg non-radioactive carrier steroids (testosterone (17/?-hydroxy-4-androsten-3-one), 5ac dihydrotestosterone (1 7,8-hydroxy-5cc-androsten-3-one) and 5x androstanediol (5cc-androstane 3,8 17/3 diol)) were added to monitor recovery losses. The metabolites were extracted as described by Fahmy et al. (1968) and separated into individual steroids by continuous elution thin layer chromatography for 2 h on Silica gel HF254+ 366 in chloroform: acetone (98: 2).
Purification of testosterone and 5x dihydrotestosterone involved sequential acetylation and hydrolysis; that for 5oc androstanediol sequential oxidation and reduction (derivative formation and chromatography systems as in Miller et al., 1974) . Although 5cx androstanediol was added as the 3fl 17,/ isomer, the methods described estimate total production of all 4 isomers of 5ca androstanediol since the isomers migrate together in the initial chromatography system and the subsequent oxidation step yields a common product, 5ac androstanedione. The percentage metabolism of testosterone and conversion to 5ac dihydrotestosterone (DHT) and 5ac androstanediol were determined by measuring the percentage incorporation of radioactive label into the appropriate metabolites after correction for recovery losses. Total 5ac-reduction was calculated by combining the percentage production of both 5ac DHT and 5ac androstanediol.
The results from these incubations are presented in Table I . There was a wide variation in metabolism of testosterone between individual tumours. In vitro addition of oestradiol produced variable results on the level of testosterone metabolized, although the most common effect was one of inhibition. Of the two 5a-reduced metabolites of testosterone, the production of 5ac androstanediol usually exceeded that of 5ac DHT, in incubations without added oestradiol. The in vitro addition of oestradiol produced variable effects on the production of 5c DHT, although in tumours with the highest control production of 5ac DHT, oestradiol was consistently inhibitory. Oestradiol inhibited the production of 50c androstanediol in all carcinomata, with a single exception, a tumour in which oestradiol exclusively affected the production of 5ac DHT. This meant that total 5a-reduction was inhibited by oestradiol in all tumours, the level of inhibition varying between 20 and 65%.
Whilst in some tumours inhibition of 5a-reduction alone would account for the effects of oestradiol on percentage metabolism of testosterone, in certain tumours, oestradiol must have also affected other steroid conversions. The production of .\4 androstenedione and 5ac androstanedione was also investigated in several tumours, but never exceeded 1% and did not appear to be influenced by in vitro addition of oestradiol.
These results indicate that oestradiol 17,8 may influence steroid metabolism by rat mammary carcinomata. In vitro addition of oestradiol reduces tumour synthesis of 5ac-reduced metabolites from testosterone, particularly 5ac androstanediol. Although this is the first report that oestrogen may affect the production of 5a-reduced steroids by mammary cancers, it is well documented that 5ac-reduction may be hormonally controlled in other tissues such as liver (Schriefers, 1967) , adrenal cortex (Kitay, Coyne and Swygert, 1970) and prostate (Farnsworth, 1972) . In common with the results presented in this study for mammary tissue, oestradiol inhibits 5ac-reduction in both adrenal cortex and prostate.
The synthesis of 5ac-reduced steroids assumes added importance in mammary tumours because both 5ac DHT and 5ac androstanediol inhibit the growth of the hormone-dependent rat mammary tumour (Huggins et al., 1959; Huggins and Mainzer, 1957) . These effects of oestradiol in decreasing tumour synthesis of 5a-reduced steroids would therefore be in keeping with oestradiol's growthpromoting effects in hormone-dependent tumours. In this context it is interesting that the same concentration of oestradiol failed to inhibit 5ac-reduction in two hormone-independent rat mammary carcinomata (Table II) . Further numbers are required before it will be possible to determine if this represents a distinction between hormone-dependent and hormoneindependent tumours.
Although the level of oestradiol added in vitro (1.5 ,ug/ml) is high compared with normal plasma levels in female rats (0-1-4.4 ng/100 ml, Hawkins et al., 1975) , the dose used in this study is comparable with that which in vitro inhibits 5ac-reduction of testosterone in prostatic tissue (Griffiths et al., 1970; Jenkins and McCafferty, 1974) and that used in predicting oestrogen sensitivity in human breast tumours (Salih, Flax and Hobbs, 1972) .
It remains to be seen, however, if oestradiol in vivo has similar effects on tumour steroidogenesis. Although oophorectomy increases the level of 5ac-reduction in rat mammary carcinomata, an effect which can be reversed by administration of oestrogen (Miller et al., 1974) , this could be caused by changes in circulating oestrogen or prolactin.
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